Firma TME Pharma, Autor bei PR-Web

TME Pharma provides update on number of outstanding shares and warrants following first warrant Y exercise period

Posted on 24. January 202426. January 2024 by Firma TME Pharma Posted in General Tagged a12, absa, brain, cancer, clinical, glioblastoma, nox, optimus, patients, radiotherapy, securities, souscription, statements, warrants, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides an update on the outstanding number of ordinary shares, Warrants Y and Warrants Z following […]

TME Pharma Announces Successful Advice Meeting With US Food And Drug Administration On NOX-A12 Development In Brain Cancer

Posted on 10. January 2024 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, glioma, merck, nox, optimus, orphan, patients, project, radiotherapy, statements, with

Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX-A12 combinations for the treatment of glioblastoma Preparatory work on-track to open IND and to have feedback on access to expedited regulatory […]

TME Pharma announces further improvement in median overall survival at 19 months follow-up in GLORIA brain cancer trial

Posted on 20. December 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, gloria, nox, optimus, patients, radiotherapy, statements, therapy, tme, vegf, with

. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 combination with radiotherapy and bevacizumab Survival rate in this cohort at 19 months is 10-fold greater than a reference cohort of matched patients receiving […]

TME Pharma annonce le vif succès de son augmentation de capital avec droits préférentiels de souscription pour un montant de 2,7 millions d’euros

Posted on 14. December 2023 by Firma TME Pharma Posted in General Tagged a12, bsa, cancer, déclarations, est, les, microsatellites, nox, optimus, patients, prospectives, radiothérapie, sont, souscription, une

L’opération a permis de lever un montant total de 2,7 millions d’euros et d’émettre 10,8 millions d’actions nouvelles. La demande importante principalement des actionnaires existants s’est élevée à 5 millions d’actions, ce qui représente un taux de souscription d’environ 47 […]

TME Pharma announces results of successful capital increase with preferential subscription rights for €2.7 million

Posted on 14. December 2023 by Firma TME Pharma Posted in General Tagged a12, absa, afm, atlas, brain, cancer, glioblastoma, market, nox, optimus, patients, radiotherapy, statements, warrants, with

Transaction raised the full amount of €2.7 million leading to the issuance of 10.8 million new shares Strong demand primarily from existing shareholders amounted to 5 million shares representing subscription rate of approx. 47% with the remaining balance covered by […]

TME Pharma annonce l’ouverture de la cotation des droits préférentiels de souscription pour l’augmentation de capital entièrement garantie de 2,7 millions d’euros

Posted on 28. November 2023 by Firma TME Pharma Posted in General Tagged a12, cancer, cas, déclarations, dps, est, les, microsatellites, nox, optimus, patients, prospectives, radiothérapie, souscription, une

Ces informations ne sont pas destinées aux résidents du Royaume-Uni, des États-Unis, de l’Australie, du Canada ou du Japon. Voir l’annexe pour une clause de non-responsabilité complète. • Le montant garanti de la transaction prolonge la visibilité de trésorerie au-delà […]

TME Pharma announces the initiation of the listing of preferential subscription rights for fully guaranteed €2.7 million capital increase

Posted on 28. November 2023 by Firma TME Pharma Posted in General Tagged a12, brain, buyback, cancer, clinical, glioblastoma, market, nox, optimus, patients, psrs, radiotherapy, statements, warrants, with

This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See Annex for full disclaimer. Guaranteed portion of the transaction will extend cash runway past regulatory milestones in Q1-2024 The financial visibility will […]

TME Pharma Launches fully guaranteed €2.7 million preferential rights issue with warrants attached combined with buyback of convertible debt

Posted on 27. November 2023 by Firma TME Pharma Posted in General Tagged a12, brain, buyback, cancer, clinical, glioblastoma, market, nox, optimus, patients, psrs, radiotherapy, statements, warrants, with

Guaranteed portion of the transaction will extend cash runway past regulatory milestones in Q1-2024 The financial visibility will allow TME Pharma to file and receive feedback from FDA on its IND and applications to expedited regulatory review pathways Current shareholders […]

TME Pharma reports H1 2023 financial results and provides business update

Posted on 30. October 202331. October 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, gloria, market, new, nox, optimus, patients, radiotherapy, statements, vegf, with

Survival data from NOX-A12 GLORIA Phase 1/2 trial in brain cancer continue to improve and have already surpassed all relevant competitors 67% overall survival at 18 months for NOX-A12 combination regimen with VEGF inhibitor and radiotherapy vs. 5% for […]

Further improvement in overall survival at 18 months to 67% for NOX-A12 combination regimen in brain cancer

Posted on 20. October 202322. October 2023 by Firma TME Pharma Posted in General Tagged a12, brain, cancer, clinical, glioblastoma, gloria, new, nox, optimus, patients, radiotherapy, statements, therapy, vegf, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that another patient has reached the 18-month survival mark after start of therapy increasing overall […]